Aventis Behring
Executive Summary
Ulrich Delvos, MD/PhD, returns to Aventis Behring as senior VP-R&D and chief scientific officer. Delvos was VitaResc Biotech AG CEO after working as managing director-European organization at Centeon, a predecessor company of Aventis' blood products business. He succeeds Peter Fuhge, PhD